Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 23

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 23
---
other than the Company’s in-house counsel, if any), the Compensation Committee must take into consideration the factors specified in Rule 5605(d)(3)(D) of the Nasdaq Listing Rules. The Compensation Committee may retain, or receive advice from, any compensation advisor they prefer, including ones that are not independent, after considering the specified factors.

To the extent permitted by law or regulation, the Compensation Committee may delegate authority to one or more members of the Compensation Committee or to one or more executives of the Company, and may form and delegate authority to one or more subcommittees and to one or more committees of executives of the Company, except that the Compensation Committee may not delegate authority to approve compensation for the Company’s CEO or its other Section 16 officers to any person or committee (other than to a subcommittee consisting exclusively of at least two members of the Committee).

During 2024, the Compensation Committee was comprised of three members: Ms. Charles (Chairperson), Ms. Chiavacci Farley, and Mr. Fry. The composition of the Compensation Committee met the requirements for independence under the current Nasdaq and SEC rules and regulations. Each member of the Compensation Committee is a “non-employee” director within the meaning of Rule 16b-3 promulgated under the Exchange Act. On April 16, 2025, Ms. Charles resigned from the Board and all committees on which she served. The charter of the Compensation Committee may be found on our website at www.conduitpharma.com/investors.

During the year ended December 31, 2024, our Compensation Committee held two meetings.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee assists the Board with its oversight of and identification of individuals qualified to become members of the Board, consistent with criteria approved by the Board, and selects, or recommends that the Board selects, director nominees; develops and recommends to the Board a set of corporate governance guidelines; oversees the evaluation of the Board; and reviews the environmental, safety, sustainability, and corporate social responsibility policies, objectives, and practices on a periodic basis.

During 2024, Nominating and Corporate Governance Committee was comprised of two members: Dr. Lewis-Hall (Chairperson) and Ms. Charles. The composition of the Nominating and Corporate Governance Committee met the requirements for independence under the current Nasdaq and SEC rules and regulations. On April 16, 2025, Ms. Charles resigned from the Board and all committees on which she served